Market Overview

Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

Share:
Related MDVN
12 Stocks Moving In Wednesday's Pre-Market Session
Benzinga's M&A Chatter for Tuesday May 3, 2016
Stocks Open Modestly Lower; Priceline Dives, Paycom Soars (Investor's Business Daily)

In a report published Wednesday, Aegis Capital Corp. reiterated its Buy rating and $100.00 price target on Medivation (NASDAQ: MDVN).

Aegis Capital noted, “Earlier today, it was disclosed that a California Superior Court judge had ruled last week against Medivation in the case of the firm vs. The Regents of The University of California (Case Number: CGC-11-510715). This case involved allegations by Medivation that a competing prostate cancer agent being developed by the privately-held firm Aragon Pharmaceuticals, ARN-509, actually belonged to Medivation. In our view, the decision may represent a perceptual setback but we note that Medivation is likely to appeal the decision, that a final resolution to this situation is likely to be a couple of years away, and that ARN-509, the competitor to Medivation's XTANDI™, is unlikely to reach the market for at least another four years. Data in chemotherapy-naive patients with XTANDI™ is scheduled to be released next year, and should enhance the competitive profile of the drug. Accordingly, we reiterate our Buy rating and maintain our 12-month price target of $100.00 per share on Medivation.”

Medivation closed on Monday at $50.03.

Latest Ratings for MDVN

DateFirmActionFromTo
Apr 2016JP MorganTerminatesOverweight
Apr 2016BMO CapitalInitiates Coverage onMarket Perform
Apr 2016SunTrust Robinson HumphreyInitiates Coverage onBuy

View More Analyst Ratings for MDVN
View the Latest Analyst Ratings

Posted-In: Aegis Capital Corp.Analyst Color Reiteration Analyst Ratings

 

Related Articles (MDVN)

View Comments and Join the Discussion!